Categories: FeaturedGeneral

Manulife Singapore Partners with Guardant Health to Transform Cancer Care

Manulife Singapore has teamed up with Guardant Health to improve access to the cutting-edge Guardant360 liquid biopsy test for eligible customers with advanced solid tumour cancers. This landmark collaboration represents a significant step in advancing cancer care in Singapore, offering patients access to personalised treatment options that may enhance clinical outcomes.

The Guardant360 liquid biopsy test provides comprehensive genomic profiling for all advanced solid tumours. It offers critical genomic and epigenomic insights from a simple blood draw, delivering results within just seven days of lab sample receipt. This non-invasive test is especially valuable for patients who lack sufficient tumour tissue for traditional biopsies, helping oncologists quickly identify appropriate treatments.

While specific eligibility criteria and program details will be announced later, this initiative promises to provide Manulife customers with broader access to guideline-recommended biomarkers across all solid cancers.

Irone Kim

View Comments

Recent Posts

AIA HYROX Singapore Draws Nearly 10,400 Racers and Over 22,000 Visitors at Singapore Urban Sports + Fitness Festival 2025

AIA HYROX Singapore wrapped up its latest edition with a powerful display of community, stamina,…

5 hours ago

Google Year in Search 2025: Singaporeans Planned Smart, Spent Wisely, and Celebrated Big for SG60

Google has released its Year in Search 2025 results, revealing what caught Singaporeans’ attention over…

10 hours ago

A-Level vs Polytechnic: Understanding different pathways offer competitive edge at SIM

SINGAPORE - Media OutReach Newswire - 6 December 2025 - Singapore's education system offers two…

1 day ago